Alphatec (ATEC) Expected to Announce Earnings on Tuesday

Alphatec (NASDAQ:ATEC) is anticipated to announce its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect Alphatec to post earnings of $0.04 per share and revenue of $212.6740 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

Alphatec Stock Up 2.0%

ATEC stock opened at $13.36 on Tuesday. Alphatec has a one year low of $8.81 and a one year high of $23.29. The company has a debt-to-equity ratio of 43.02, a quick ratio of 1.24 and a current ratio of 1.99. The company has a fifty day moving average of $17.90 and a 200-day moving average of $17.21. The stock has a market capitalization of $1.98 billion, a PE ratio of -12.85 and a beta of 1.01.

Insider Activity at Alphatec

In related news, COO Scott Lish sold 19,900 shares of the business’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $19.64, for a total transaction of $390,836.00. Following the transaction, the chief operating officer directly owned 641,432 shares of the company’s stock, valued at approximately $12,597,724.48. The trade was a 3.01% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Craig E. Hunsaker sold 37,358 shares of the company’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $14.71, for a total value of $549,536.18. Following the completion of the transaction, the executive vice president owned 1,173,025 shares of the company’s stock, valued at approximately $17,255,197.75. This represents a 3.09% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 2,281,125 shares of company stock valued at $46,711,578 over the last quarter. Company insiders own 22.80% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Van ECK Associates Corp raised its position in shares of Alphatec by 26.1% in the 4th quarter. Van ECK Associates Corp now owns 11,318 shares of the medical technology company’s stock valued at $238,000 after purchasing an additional 2,342 shares in the last quarter. CIBC Bancorp USA Inc. bought a new stake in shares of Alphatec in the third quarter worth $180,000. Voleon Capital Management LP acquired a new stake in Alphatec in the third quarter valued at $290,000. Prelude Capital Management LLC boosted its stake in Alphatec by 38.6% during the 3rd quarter. Prelude Capital Management LLC now owns 20,338 shares of the medical technology company’s stock valued at $296,000 after acquiring an additional 5,666 shares during the last quarter. Finally, Man Group plc acquired a new position in Alphatec during the 3rd quarter worth $283,000. 66.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ATEC. Stifel Nicolaus assumed coverage on Alphatec in a report on Tuesday, October 28th. They issued a “buy” rating and a $20.00 price target for the company. TD Cowen reaffirmed a “buy” rating on shares of Alphatec in a research note on Tuesday, January 27th. Wall Street Zen raised Alphatec from a “hold” rating to a “buy” rating in a report on Saturday, January 31st. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price target on shares of Alphatec in a research report on Monday, January 12th. Finally, Loop Capital set a $25.00 price objective on Alphatec in a research report on Wednesday, December 10th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $22.82.

Alphatec Company Profile

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.